Nanohale AG (ETR:FYB)

BRIEF

published on 05/15/2024 at 07:35, 1 year 8 months ago

MS Pharma Partners with Formycon for Commercialization of FYB203 in MENA

MENA Region MS Pharma Biosimilar Formycon FYB203
PRESS RELEASE

published on 05/15/2024 at 07:30, 1 year 8 months ago

MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
Formycon AG partners with MS Pharma for commercializing FYB203, a biosimilar candidate to Eylea in the MENA region, strengthening biosimilar portfolio and local production

Formycon AG MS Pharma Biosimilar FYB203 Eylea
BRIEF

published on 05/08/2024 at 07:35, 1 year 8 months ago

Formycon Reports Steady Performance in Q1 2024 Despite Challenges

Formycon AG Q1 2024 Financial Results Biosimilars Development Gedeon Richter Partnership Biopharmaceutical Market
PRESS RELEASE

published on 05/08/2024 at 07:30, 1 year 8 months ago

Formycon reports on successful operating business and financial figures for the first quarter of 2024
Formycon reports successful Q1 2024 operating business and financial figures, including acquisitions and strategic investments. Revenue at €17.7 million. Invitation to conference call

Acquisitions Financial Figures Strategic Investments Q1 2024 Formycon
BRIEF

published on 05/07/2024 at 11:05, 1 year 8 months ago

Formycon Announces Key Details for Annual General Meeting 2024 and Changes in Supervisory Board

Annual General Meeting Corporate Governance Supervisory Board Formycon AG Biosimilars
PRESS RELEASE

published on 05/07/2024 at 11:00, 1 year 8 months ago

Formycon invites to the Annual General Meeting on June 12, 2024 in Munich
Formycon AG invites shareholders to Annual General Meeting in Munich on June 12, 2024, to elect new Supervisory Board members and expand the board to enhance international focus and expertise

Annual General Meeting Financial Expertise Supervisory Board Formycon AG International Focus
BRIEF

published on 05/02/2024 at 07:35, 1 year 8 months ago

Formycon AG Announces First Quarter 2024 Conference Call

Conference Call Investor Conferences Formycon AG Financial Outlook Q1 2024 Results
PRESS RELEASE

published on 05/02/2024 at 07:30, 1 year 8 months ago

Formycon hosts conference call on the results of the first quarter 2024
Formycon AG to host conference call discussing first quarter 2024 results, financial figures, and 2024 outlook. Management to participate in investor conferences globally

Conference Call Investor Conferences Financial Figures Formycon AG First Quarter 2024 Results
BRIEF

published on 04/25/2024 at 07:35, 1 year 9 months ago

Formycon Announces Strong Financial Results for 2023 and Provides Outlook for 2024

2024 Outlook Formycon AG Biosimilars 2023 Financial Results Biopharmaceuticals
PRESS RELEASE

published on 04/25/2024 at 07:30, 1 year 9 months ago

Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
Formycon reports audited annual results for the financial year 2023, exceeding guidance with an 83% increase in group revenue. Positive EBITDA and outlook for 2024 announced

2024 Outlook Financial Year 2023 Group Revenue Annual Results Formycon

Published on 01/30/2026 at 14:00, 4 hours 57 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 10 hours 22 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 10 hours 57 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 16 hours 42 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 18 hours 57 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

Published on 01/30/2026 at 18:31, 25 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/30/2026 at 18:30, 26 minutes ago

HOL-Holdings in Company
Published on 01/30/2026 at 18:23, 33 minutes ago

TVR-Total Voting Rights
Published on 01/30/2026 at 18:17, 39 minutes ago

POS-Transaction in Own Shares
Published on 01/30/2026 at 18:17, 39 minutes ago

Holding(s) in Company

View all EQS

Published on 01/30/2026 at 17:45, 1 hour 12 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 10 hours 57 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 1 hour ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 1 hour ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News